Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of targeted therapy for atopic dermatitis
ChiCTR2300076625Phase 4Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab, upadacitinib and abrocitinib in atopic dermatitis (AD) (4 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Eczema Area and Severity Index (EASI), Intestinal flora and 2 more. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2300076625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076625.